Quanterix Stock Price, News & Analysis (NASDAQ:QTRX) $23.20 -0.40 (-1.69%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$22.98▼$24.1350-Day Range$19.54▼$27.9652-Week Range$10.02▼$28.77Volume370,426 shsAverage Volume351,092 shsMarket Capitalization$877.66 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Quanterix MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside37.9% Upside$32.00 Price TargetShort InterestHealthy3.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$501,970 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.78) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.49 out of 5 starsMedical Sector125th out of 955 stocksAnalytical Instruments Industry6th out of 25 stocks 3.6 Analyst's Opinion Consensus RatingQuanterix has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Quanterix has a forecasted upside of 37.9% from its current price of $23.20.Amount of Analyst CoverageQuanterix has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.12% of the float of Quanterix has been sold short.Short Interest Ratio / Days to CoverQuanterix has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quanterix has recently decreased by 1.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldQuanterix does not currently pay a dividend.Dividend GrowthQuanterix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTRX. Previous Next 3.0 News and Social Media Coverage News SentimentQuanterix has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Quanterix this week, compared to 1 article on an average week.Search Interest9 people have searched for QTRX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Quanterix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quanterix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $501,970.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Quanterix is held by insiders.Percentage Held by Institutions86.64% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Quanterix are expected to grow in the coming year, from ($0.78) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quanterix is -22.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quanterix is -22.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuanterix has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Quanterix Stock (NASDAQ:QTRX)Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.Read More QTRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTRX Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comHere's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to BuyNovember 29, 2023 | finance.yahoo.comDoes Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?December 6, 2023 | Edge On The Street (Ad)Energy Storage Trend Ignites Frenzy Over Vanadium SupplyAs the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.November 28, 2023 | msn.comQuanterix (QTRX) Price Target Increased by 6.67% to 32.64November 13, 2023 | finance.yahoo.comQuanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNovember 13, 2023 | finance.yahoo.comWall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?November 9, 2023 | markets.businessinsider.comHold Rating on Quanterix Amid Strong Q3 Performance and Anticipated ChallengesNovember 9, 2023 | markets.businessinsider.comQuanterix’s Robust Growth and Promising Alzheimer’s Diagnostics Drive Buy Rating RecommendationDecember 6, 2023 | Edge On The Street (Ad)Energy Storage Trend Ignites Frenzy Over Vanadium SupplyAs the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.November 8, 2023 | finance.yahoo.comQuanterix Corporation (NASDAQ:QTRX) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | seekingalpha.comQuanterix Corporation 2023 Q3 - Results - Earnings Call PresentationNovember 7, 2023 | uk.finance.yahoo.comQuanterix Releases Operating Results for Third Quarter 2023November 6, 2023 | finance.yahoo.comQuanterix Corp (QTRX) Raises Full-Year Revenue Expectations Following Q3 2023 ResultsNovember 6, 2023 | seekingalpha.comQuanterix Corporation: Going For Three In A RowNovember 3, 2023 | benzinga.comA Preview Of Quanterix's EarningsOctober 30, 2023 | finance.yahoo.comQuanterix to Report Third Quarter 2023 Financial Results on November 7, 2023October 28, 2023 | markets.businessinsider.comQuanterix’s Promising Position in Alzheimer’s Disease Diagnostics Market Prompts Buy RatingOctober 24, 2023 | stockhouse.comQuanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's DiseaseOctober 24, 2023 | finance.yahoo.comQuanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s DiseaseOctober 24, 2023 | finance.yahoo.comQuanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease DetectionOctober 23, 2023 | finance.yahoo.comQuanterix (NASDAQ:QTRX) shareholders have earned a 110% return over the last yearOctober 11, 2023 | markets.businessinsider.comQuanterix’s Competitive Edge in Alzheimer’s BBBM Field Upholds Buy Rating: An Analyst’s PerspectiveOctober 3, 2023 | finance.yahoo.comQuanterix (QTRX): A Closer Look at Its Modestly Undervalued StatusSeptember 28, 2023 | benzinga.comQuanterix CEO to Speak at Goldman Sachs Alzheimer's Disease DaySeptember 28, 2023 | finance.yahoo.comQuanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease DaySeptember 28, 2023 | markets.businessinsider.comAnalyst Expectations for Quanterix's FutureSeptember 28, 2023 | msn.comQuanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?See More Headlines Receive QTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTRX CUSIPN/A CIK1503274 Webwww.quanterix.com Phone(617) 301-9400FaxN/AEmployees370Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$34.00 Low Stock Price Target$30.00 Potential Upside/Downside+37.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,700,000.00 Net Margins-33.03% Pretax Margin-32.47% Return on Equity-10.81% Return on Assets-8.96% Debt Debt-to-Equity RatioN/A Current Ratio10.84 Quick Ratio10.27 Sales & Book Value Annual Sales$105.52 million Price / Sales8.32 Cash FlowN/A Price / Cash FlowN/A Book Value$9.69 per share Price / Book2.39Miscellaneous Outstanding Shares37,830,000Free Float34,728,000Market Cap$877.66 million OptionableNot Optionable Beta1.27 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Masoud Toloue Ph.D. (Age 42)President, CEO & Director Comp: $957.03kDr. David R. Walt Ph.D. (Age 70)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $47.25kDr. Mark T. Roskey Ph.D. (Age 63)Senior Vice President of Strategic Partnerships Comp: $495.03kMr. Michael A. Doyle (Age 67)Executive Director of Finance Comp: $570.14kMs. Vandana Sriram CPA (Age 49)Chief Financial Officer Mr. Daniel Pikora (Age 47)Chief Operating Officer Dr. David C. Duffy Ph.D. (Age 52)Senior VP of Research & Development and CTO Comp: $299.05kMs. Alexandra PhillipsSenior VP & Chief Information OfficerMs. Laurie A. Churchill (Age 52)Senior VP, General Counsel & Secretary David PanzerellaVice President of SalesMore ExecutivesKey CompetitorsCytek BiosciencesNASDAQ:CTKBEyePoint PharmaceuticalsNASDAQ:EYPTNautilus BiotechnologyNASDAQ:NAUTFluidigmNASDAQ:FLDMAkoya BiosciencesNASDAQ:AKYAView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 10,852 shares on 11/30/2023Ownership: 0.082%Deutsche Bank AGSold 768,052 shares on 11/24/2023Ownership: 0.106%Graham Capital Management L.P.Bought 10,557 shares on 11/22/2023Ownership: 0.028%Jacobs Levy Equity Management Inc.Sold 64,421 shares on 11/17/2023Ownership: 0.476%Public Employees Retirement System of OhioSold 2,180 shares on 11/16/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions QTRX Stock Analysis - Frequently Asked Questions Should I buy or sell Quanterix stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTRX shares. View QTRX analyst ratings or view top-rated stocks. What is Quanterix's stock price target for 2024? 5 brokers have issued 1-year price objectives for Quanterix's stock. Their QTRX share price targets range from $30.00 to $34.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts. How have QTRX shares performed in 2023? Quanterix's stock was trading at $13.85 on January 1st, 2023. Since then, QTRX shares have increased by 67.5% and is now trading at $23.20. View the best growth stocks for 2023 here. When is Quanterix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our QTRX earnings forecast. How were Quanterix's earnings last quarter? Quanterix Co. (NASDAQ:QTRX) announced its earnings results on Monday, November, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.14. The company earned $31.33 million during the quarter, compared to analysts' expectations of $27.79 million. Quanterix had a negative trailing twelve-month return on equity of 10.81% and a negative net margin of 33.03%. What ETFs hold Quanterix's stock? ETFs with the largest weight of Quanterix (NASDAQ:QTRX) stock in their portfolio include Simplify Health Care ETF (PINK) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Invesco Nasdaq Future Gen 200 ETF (QQQS). What guidance has Quanterix issued on next quarter's earnings? Quanterix issued an update on its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $118.00 million-$120.00 million, compared to the consensus revenue estimate of $115.21 million. What is Kevin Hrusovsky's approval rating as Quanterix's CEO? 15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees. What other stocks do shareholders of Quanterix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA). When did Quanterix IPO? (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers. Who are Quanterix's major shareholders? Quanterix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Invesco Ltd. (2.92%), Lord Abbett & CO. LLC (2.70%), FMR LLC (2.21%), Ashford Capital Management Inc. (2.11%), Platinum Investment Management Ltd. (1.76%) and Ameriprise Financial Inc. (1.68%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Masoud Toloue, Michael A Doyle and William P Donnelly. View institutional ownership trends. How do I buy shares of Quanterix? Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:QTRX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quanterix Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.